Report : US Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Type (IgG, IgM, IgA, and Others), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and End User (Hospitals, Specialty Clinics, and Others)
US Intravenous Immunoglobulin Market for Hospitals Segment to Grow Significantly During 2022–2028
According to our latest research study on “US Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Country Analysis – by Type, Application, Distribution Channel, and End User,” the market was valued at US$ 4,439.26 million in 2022 and is projected to reach US$ 7,105.63 million by 2028; it is estimated to grow at a CAGR 8.2% during 2023–2028. The report highlights trends prevailing in the market and factors governing the US intravenous immunoglobulin market growth.
Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. Individuals with immunoglobulin deficiency require the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIGs are extracted from human plasma. These antibodies are used in the treatment of various immunological, hematological, and neurological illnesses. Factors such as rising immunodeficiency disease prevalence and increasing geriatric population in the US drive the US intravenous immunoglobulin market growth. However, adverse effects of immunoglobulin therapy hamper the market growth.
Increasing Geriatric Population Favors US Intravenous Immunoglobulin Market Growth
The detection and destruction of autoreactive or malignant cells is one of the known functions of the immune system. Aging hampers the capability of a person to fight against infections and malignant cells due to a reduction in the system’s ability to produce T-cells or B-cells. These changes occurring in the immune system due to aging are called immunosenescence. Due to the weakening of the immune system or immunosenescence, the geriatric population is more susceptible to immunodeficiency diseases. To treat these diseases, IVIG treatment is prescribed to elderly patients suffering from these diseases, as these immunoglobulins are safe and can be tolerated by the person’s body.
As per the 2020 PROFILE OF OLDER AMERICANS report, 54.1 million people in the US—30 million women and 24.1 million men—were aged 65 and above in 2019. In 2019, 16% of the total population was aged 65 and above, and it is expected to increase to 21.6% by 2040. Since 2009, the elderly population has increased by 36% (with the addition of 14.4 million) in the US. As an older person’s body is prone to several infections and diseases, an increase in the geriatric population triggers the demand for immunological therapies, including IVIGs.
Based on application, the US intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment led the market in 2022 with a share of 21.89% and is expected to retain its dominance during the forecast period by holding 22.99% of the total market by 2028. The market growth for the immunodeficiency diseases segment is attributed to the surging prevalence of immunodeficiency diseases in the US. Immunodeficiency diseases are categorized as primary (congenital) and secondary (acquired) immunodeficiency diseases. Among both, primary immunodeficiency diseases (PIDDs) can be characterized into 400 different types. According to the Journal of Allergy and Clinical Immunology, the prevalence of PIDD in the US is estimated at 1 in 2,000 individuals. IVIG administration is the apparent treatment of choice against humoral primary immunodeficiencies, as these patients cannot mount an effective immune response against pathogens.
Impact of COVID-19 Pandemic on US Intravenous Immunoglobulin Market
The COVID-19 pandemic hampered the US intravenous immunoglobulin market. The COVID-19 Treatment Guidelines Panel prohibited the use of intravenous immunoglobulin (IVIG) to treat acute COVID-19 in children and adults, excluding in a clinical trial (AIII). Thus, the demand for intravenous immunoglobulin (IVIG) decreased during the pandemic. For instance, in February 2022, CSL reported that its core franchise, the immunoglobulin portfolio, was impacted by industrywide constraints on plasma collections during the COVID-19 crisis. Immunoglobulin products are manufactured from plasma, and travel restrictions and lockdowns made it difficult for people to donate plasma at CSL's collection centers. CSL stated immunoglobulin sales declined 9% in the first half-year of 2022.
Takeda Pharmaceuticals Co Ltd, Grifols SA, Pfizer Inc, ADMA Biologics, Bio Products Laboratory Ltd, Octapharma AG, Kedrion SpA, CSL Ltd, LFB Group, and Prothya Biosolutions BV are a few leading companies operating in the US intravenous immunoglobulin market.
The Report Segments US Intravenous Immunoglobulin Market as Follows:
The US intravenous immunoglobulin market is segmented on the basis of type, application, distribution channel, and end user. Based on type, the market is segmented into IgG, IgA, IgM, and Others. Based on application, the US intravenous immunoglobulin market is segmented into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. Based on distribution channel, the US intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. By end-user, the US intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com